Elsevier

Molecular Therapy — Nucleic Acids Template

Write in a clean editor, then format for Molecular Therapy — Nucleic Acids in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.

About the Molecular Therapy — Nucleic Acids format

Molecular Therapy — Nucleic Acids is a peer-reviewed journal published by Elsevier, covering RNA Interference and Gene Delivery, MicroRNA in disease regulation, Cancer-related molecular mechanisms research.

PublisherElsevier
Reference styleNumbered (Elsevier)
Numbered — [1], [2] in the text
[1] A. Smith, B. Jones, C. Lee, A representative article title, Molecular Therapy — Nucleic Acids 12 (2023) 45–58.

Formats any DOI in Molecular Therapy — Nucleic Acids style. No sign-up.

Publishes research inRNA Interference and Gene Delivery MicroRNA in disease regulation Cancer-related molecular mechanisms research CRISPR and Genetic Engineering Circular RNAs in diseases
ISSN2162-2531
Citation impact (2-yr)4.74
h-index130
i10-index2,215
Total citations117,949
Article processing charge$3,900
Open accessYes
Top institutions publishing hereInserm
Journal websitewww.sciencedirect.com
You getA submission-ready PDF and the editable LaTeX source — ready to submit.

Papers published in Molecular Therapy — Nucleic Acids per year

78
2014
55
2015
133
2016
186
2017
218
2018
338
2019
385
2020
336
2021
324
2022
301
2023
309
2024
358
2025

Citation impact of Molecular Therapy — Nucleic Acids by publication year

5.7K
2014
5.6K
2015
6.3K
2016
10.9K
2017
12.1K
2018
21.5K
2019
19.1K
2020
11.7K
2021
6.4K
2022
4.9K
2023
2.5K
2024
1.2K
2025

Citations each year’s papers have accumulated so far — the most recent years are still building up.

Most-cited papers in Molecular Therapy — Nucleic Acids

Off-target Effects in CRISPR/Cas9-mediated Genome Engineering

Xiaohui Zhang, Louis Y. Tee, Xiaogang Wang et al. · 1 Jan 2015

CRISPR/Cas9 is a versatile genome-editing technology that is widely used for studying the functionality of genetic elements, creating genetically modified organisms as well as preclinical research of genetic disorders. However, the high frequency of off-target activity (≥50%)-RGEN (RNA-guided endonuclease)-induced mutations at sites other than the intended on-target site-is one major concern, especially for therapeutic and…

1,301 citations Cite SaveGo to paper →
siRNA Versus miRNA as Therapeutics for Gene Silencing

Jenny K.W. Lam, Michael Y.T. Chow, Yu Zhang et al. · 1 Jan 2015

Discovered a little over two decades ago, small interfering RNAs (siRNAs) and microRNAs (miRNAs) are noncoding RNAs with important roles in gene regulation. They have recently been investigated as novel classes of therapeutic agents for the treatment of a wide range of disorders including cancers and infections. Clinical trials of siRNA- and miRNA-based drugs have…

1,054 citations Cite SaveGo to paper →
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines

Kimberly J. Hassett, Kerry E. Benenato, Eric Jacquinet et al. · 10 Feb 2019

mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust…

Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine

Chiranjib Chakraborty, Ashish Ranjan Sharma, Garima Sharma et al. · 12 Jun 2017

In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are some of the most important biopharmaceuticals that are in commercial space as future medicines. This review summarizes the patents of miRNA- and siRNA-based new drugs, and also provides a snapshot about significant biopharmaceutical companies that are investing for the therapeutic development…

Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

Nathan M. Belliveau, Jens Huft, Paulo J.C. Lin et al. · 1 Jan 2012

Lipid nanoparticles (LNP) are the leading systems for in vivo delivery of small interfering RNA (siRNA) for therapeutic applications. Formulation of LNP siRNA systems requires rapid mixing of solutions containing cationic lipid with solutions containing siRNA. Current formulation procedures employ macroscopic mixing processes to produce systems 70-nm diameter or larger that have variable siRNA encapsulation…

Molecular Therapy — Nucleic Acids template — frequently asked questions

How do I write a paper in the Molecular Therapy — Nucleic Acids format?
In DocuGuru you write your manuscript in a normal editor — no LaTeX setup required — and select the Molecular Therapy — Nucleic Acids template. When you export, DocuGuru compiles the paper into the official Elsevier format and hands you a submission-ready PDF along with the editable LaTeX source.
What reference style does Molecular Therapy — Nucleic Acids use?
Molecular Therapy — Nucleic Acids uses Numbered (Elsevier) references, shown as numbered [1], [2] markers in the text. DocuGuru formats every in-text citation and the reference list in this exact style automatically. A reference appears like this: [1] A. Smith, B. Jones, C. Lee, A representative article title, Molecular Therapy — Nucleic Acids 12 (2023) 45–58.
Do I need to know LaTeX to submit to Molecular Therapy — Nucleic Acids?
No. DocuGuru generates the elsarticle LaTeX class and compiles the PDF for you in the background, so you get a Elsevier-ready Molecular Therapy — Nucleic Acids document without writing any LaTeX. If you do want it, the LaTeX source is included in the export.
Can I import an existing draft into the Molecular Therapy — Nucleic Acids template?
Yes. Paste or upload your current manuscript — Word, LaTeX, Markdown, or plain text — and DocuGuru reflows it into the Molecular Therapy — Nucleic Acids format with correct headings, figures, tables, and numbered citations.
Who publishes Molecular Therapy — Nucleic Acids?
Molecular Therapy — Nucleic Acids is a multidisciplinary journal published by Elsevier. DocuGuru's Molecular Therapy — Nucleic Acids template matches Elsevier's official submission format.
Can I export a submission-ready Molecular Therapy — Nucleic Acids PDF?
Yes — DocuGuru produces a PDF built with the official Molecular Therapy — Nucleic Acids template (the elsarticle class) that is ready to submit to Elsevier, together with the matching LaTeX source files.
How much does the Molecular Therapy — Nucleic Acids template cost?
You can start writing in the Molecular Therapy — Nucleic Acids template for free. Exporting the final submission-ready Molecular Therapy — Nucleic Acids PDF and LaTeX source is part of DocuGuru's paid plans — see the app for current pricing.
Use the Molecular Therapy — Nucleic Acids template